These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 26493618

  • 1. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma.
    Singhi AD, Krasinskas AM, Choudry HA, Bartlett DL, Pingpank JF, Zeh HJ, Luvison A, Fuhrer K, Bahary N, Seethala RR, Dacic S.
    Mod Pathol; 2016 Jan; 29(1):14-24. PubMed ID: 26493618
    [Abstract] [Full Text] [Related]

  • 2. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
    Brich S, Bozzi F, Perrone F, Tamborini E, Cabras AD, Deraco M, Stacchiotti S, Dagrada GP, Pilotti S.
    Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
    [Abstract] [Full Text] [Related]

  • 3. Inactivation of Bap1 Cooperates with Losses of Nf2 and Cdkn2a to Drive the Development of Pleural Malignant Mesothelioma in Conditional Mouse Models.
    Kukuyan AM, Sementino E, Kadariya Y, Menges CW, Cheung M, Tan Y, Cai KQ, Slifker MJ, Peri S, Klein-Szanto AJ, Rauscher FJ, Testa JR.
    Cancer Res; 2019 Aug 15; 79(16):4113-4123. PubMed ID: 31151962
    [Abstract] [Full Text] [Related]

  • 4. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
    Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, Maillet D, Galateau-Sallé F, Villenet C, Sebda S, Goracci A, Byrnes G, McKay JD, Figeac M, Glehen O, Gilly FN, Foll M, Fernandez-Cuesta L, Brevet M.
    J Thorac Oncol; 2017 Apr 15; 12(4):724-733. PubMed ID: 28034829
    [Abstract] [Full Text] [Related]

  • 5. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A, Prabhakaran S, Pulford E, Hocking AJ, Godbolt D, Ziad F, Pandita A, Wessels A, Hussey M, Russell PA, Klebe S.
    Pathology; 2024 Aug 15; 56(5):662-670. PubMed ID: 38789301
    [Abstract] [Full Text] [Related]

  • 6. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB, Dacic S, Miller C, Cheung S, Churg A.
    Arch Pathol Lab Med; 2018 Dec 15; 142(12):1549-1553. PubMed ID: 30059257
    [Abstract] [Full Text] [Related]

  • 7. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM, McElherne J, Minor A, Keller-Ramey J, Dunning R, Husain AN, Vigneswaran W, Fitzpatrick C, Krausz T.
    Hum Pathol; 2017 Feb 15; 60():86-94. PubMed ID: 27771374
    [Abstract] [Full Text] [Related]

  • 8. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival.
    Krasinskas AM, Bartlett DL, Cieply K, Dacic S.
    Mod Pathol; 2010 Apr 15; 23(4):531-8. PubMed ID: 20081810
    [Abstract] [Full Text] [Related]

  • 9. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
    Sa-Ngiamwibool P, Hamasaki M, Kinoshita Y, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Kasai T, Kushitani K, Takeshima Y, Hiroshima K, Iwasaki A, Nabeshima K.
    Lung Cancer; 2023 Jan 15; 175():27-35. PubMed ID: 36442384
    [Abstract] [Full Text] [Related]

  • 10. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G, Özekinci S.
    Eur Rev Med Pharmacol Sci; 2023 Oct 15; 27(20):10001-10007. PubMed ID: 37916370
    [Abstract] [Full Text] [Related]

  • 11. Molecular characterization of diffuse malignant peritoneal mesothelioma.
    Hung YP, Dong F, Torre M, Crum CP, Bueno R, Chirieac LR.
    Mod Pathol; 2020 Nov 15; 33(11):2269-2279. PubMed ID: 32504035
    [Abstract] [Full Text] [Related]

  • 12. Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.
    Kinoshita Y, Hamasaki M, Yoshimura M, Matsumoto S, Iwasaki A, Nabeshima K.
    Mod Pathol; 2020 Feb 15; 33(2):235-244. PubMed ID: 31231129
    [Abstract] [Full Text] [Related]

  • 13. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
    Walts AE, Hiroshima K, McGregor SM, Wu D, Husain AN, Marchevsky AM.
    Diagn Cytopathol; 2016 Jul 15; 44(7):599-606. PubMed ID: 27121152
    [Abstract] [Full Text] [Related]

  • 14. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
    Joseph NM, Chen YY, Nasr A, Yeh I, Talevich E, Onodera C, Bastian BC, Rabban JT, Garg K, Zaloudek C, Solomon DA.
    Mod Pathol; 2017 Feb 15; 30(2):246-254. PubMed ID: 27813512
    [Abstract] [Full Text] [Related]

  • 15. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
    Wu D, Hiroshima K, Yusa T, Ozaki D, Koh E, Sekine Y, Matsumoto S, Nabeshima K, Sato A, Tsujimura T, Yamakawa H, Tada Y, Shimada H, Tagawa M.
    Ann Diagn Pathol; 2017 Feb 15; 26():31-37. PubMed ID: 28038708
    [Abstract] [Full Text] [Related]

  • 16. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
    Chevrier M, Monaco SE, Jerome JA, Galateau-Salle F, Churg A, Dacic S.
    Cancer Cytopathol; 2020 Dec 15; 128(12):939-947. PubMed ID: 32678499
    [Abstract] [Full Text] [Related]

  • 17. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC, Sheffield BS, Rodriguez S, Thompson K, Tse CH, Gown AM, Churg A.
    Am J Surg Pathol; 2016 Jan 15; 40(1):120-6. PubMed ID: 26448191
    [Abstract] [Full Text] [Related]

  • 18. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W, Gazzo S, Blanchet M, Isaac S, Piaton E, Villeneuve L, Glehen O, Gilly FN, Brevet M.
    Cytopathology; 2020 Jan 15; 31(1):5-11. PubMed ID: 31713897
    [Abstract] [Full Text] [Related]

  • 19. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A, Sheffield BS, Galateau-Salle F.
    Arch Pathol Lab Med; 2016 Apr 15; 140(4):318-21. PubMed ID: 26288396
    [Abstract] [Full Text] [Related]

  • 20. Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma.
    Davidson B, Holth A, Hummel C, Flatmark K, Torgunrud A.
    Appl Immunohistochem Mol Morphol; 2024 Jul 01; 32(6):280-284. PubMed ID: 38812360
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.